top of page
psilocybin-connectivity-2427463299.jpg

Notable Research for Treating Addiction

Ibogaine Treatment for Opioid Dependence

This study examined the pharmacokinetics and safety profile of ibogaine in the treatment of opioid dependence. Preliminary efficacy measures suggested that ibogaine could help reduce drug cravings and withdrawal symptoms.

​

Read more

Ibogaine for Opioid Use Disorder: Detoxification Outcomes

This review covered the use of ibogaine for treating substance dependence, including opioid use disorder. It summarized multiple case series and open-label studies indicating that ibogaine can help reduce withdrawal symptoms and cravings.

​

Read more

Ibogaine and Opioid Addiction

This observational study reported on the use of ibogaine, a psychoactive substance from the African plant Tabernanthe iboga, in treating opioid addiction. The findings indicated that ibogaine can significantly reduce withdrawal symptoms and cravings, facilitating long-term abstinence in many cases. 

​

Read more

Treating Addiction: Perspectives from EEG and Imaging Studies on Psychedelics

This review outlines EEG and brain imaging studies evaluating the effects of psychedelics on the brain, highlighting their efficacy in treating depression and alcohol-use disorders.

​

Read more

Psilocybin-Assisted Treatment for Alcohol Dependence

This study explored the effects of psilocybin on individuals with alcohol dependence. Participants underwent two psilocybin sessions combined with motivational enhancement therapy. Results showed significant reductions in drinking behavior and an increase in abstinence rates, indicating the potential of psilocybin in treating alcohol use disorders.

​

Read more

Classic Psychedelics for Reducing Alcohol Consumption

A systematic review of human and animal studies on classic psychedelics (LSD, psilocybin, ayahuasca, mescaline) indicates promising data for reducing alcohol consumption, particularly with psilocybin.

​

Read more

Classic Psychedelics and Addiction Treatment

A comprehensive review of historical and recent clinical research on classic hallucinogens in addiction treatment, noting significant beneficial effects of high-dose LSD in treating alcoholism.

​

Read more

The Therapeutic Effect of Psilocybin in Addiction

This systematic review specifically assesses the efficacy of psilocybin in patients with a SUD or non-substance-related disorder with no publication date restrictions in our search strategy.

​

Read more

Psilocybin for Smoking Cessation

Conducted by Johns Hopkins University, this study found that psilocybin-assisted psychotherapy significantly improved smoking cessation rates. Twelve out of fifteen participants (80%) remained abstinent six months after treatment, compared to typical success rates of about 35% with traditional methods.

​

Read more

This open-label pilot study assessed the long-term effects of psilocybin-facilitated smoking cessation combined with cognitive behavioral therapy (CBT). Participants received two to three moderate to high doses of psilocybin (20 and 30 mg/70 kg) and were followed up for at least 12 months. At the 12-month follow-up, 67% of participants were confirmed as smoking abstinent. At a longer-term follow-up (mean interval of 30 months), 60% of participants remained abstinent. Additionally, 86.7% of participants rated their psilocybin experiences among the five most personally meaningful and spiritually significant experiences of their lives. The study suggests that psilocybin, in the context of a structured treatment program, holds considerable promise for promoting long-term smoking abstinence.

​

Read more

Ayahuasca and Substance Dependence

This study explored the use of ayahuasca, a traditional Amazonian brew, in treating substance dependence. Participants reported significant reductions in substance use and improvements in mental health following ayahuasca ceremonies, suggesting potential benefits for addiction treatment.

​

Read more

Effects of Ayahuasca and its Alkaloids on Substance Use Disorders

This systematic review provides an updated analysis of the effects of ayahuasca and its alkaloids on substance use disorders, covering studies from 2016 to 2020. The review includes both preclinical and human studies, examining the biochemical and psychological mechanisms through which ayahuasca may reduce cravings, withdrawal symptoms, and substance use. The findings suggest that ayahuasca could play a significant role in treating various forms of addiction.

​

Read more

MDMA and PTSD-related Substance Use

Although primarily focused on PTSD, this study noted significant secondary benefits for participants with co-occurring substance use disorders. The reduction in PTSD symptoms often led to decreased substance use, highlighting the potential for MDMA-assisted therapy in addressing addiction indirectly.

​

Read more

LSD and Alcoholism

This meta-analysis of six randomized controlled trials from the 1960s and 1970s found that a single dose of LSD, combined with psychotherapy, significantly reduced alcohol misuse. The study concluded that LSD could be a valuable adjunct in the treatment of alcoholism.

​

Read more

DISCLAIMER: THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE OR REFERRALS

 

No material on this site is intended to be a substitute for professional medical advice, diagnosis, or treatment. The information on this website is for educational and informational purposes only and does not constitute providing medical advice or professional services. Do not use the information provided for diagnosing or treating a health problem or disease. Those seeking personal medical advice should consult with a licensed physician or other qualified healthcare provider. Do not disregard professional medical advice or delay in seeking it because of something you have read on this website. 

 

At this time in the United States, ketamine is the only legal psychedelic medicine.

 

Neither Nevada Coalition for Psychedelic Medicines, nor its employees or representatives, nor any contributor to this website, makes any representations, express or implied, with respect to the information provided herein or to its use. Nevada Coalition for Psychedelic Medicines DOES NOT encourage, endorse, or promote any illegal activities or reckless drug use, and bears no responsibility for anyone’s decision to do so. 

  • Instagram
  • Facebook
  • X

NAVIGATION

 

CONTACT

bottom of page